Literature DB >> 10584215

Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.

S Hannongbua1, P Pungpo, J Limtrakul, P Wolschann.   

Abstract

Quantitative structure-activity relationships (QSAR) and Comparative Molecular Field Analysis (CoMFA) have been applied in order to explain the structural requirements of HIV-1 reverse transcriptase (HIV-1 RT) inhibitory activity of TIBO derivatives on the MT-4 cells. The best QSAR model is satisfactory in both statistical significance and predictive ability. The derived structural descriptors indicate the importance of electronic contributions toward the HIV-1 RT inhibition of this class of compounds. However, it could not reveal any hydrophobic influence because of high collinearity between C2 and log P variables. In order to cope with steric interaction in the correlation, 3D-QSAR was performed using CoMFA. The obtained CoMFA model shows high predictive ability, rcv2 = 0.771, and clearly demonstrates its potential in the steric feature of the molecules through contour maps, explaining a majority (81.8%) of the variance in the data. Consequently, these results can be useful in identifying the structural requirements of TIBO derivatives and helpful for better understanding the HIV-1 RT inhibition. Eventually, they provide a beneficial basis to design new and more potent inhibitors of HIV-1 RT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584215     DOI: 10.1023/a:1008013917905

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  17 in total

1.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

2.  Structure-activity correlation study of HIV-1 inhibitors: electronic and molecular parameters.

Authors:  S Hannongbua; L Lawtrakul; J Limtrakul
Journal:  J Comput Aided Mol Des       Date:  1996-04       Impact factor: 3.686

3.  Change correlations in structure-activity studies using multiple regression analysis.

Authors:  J G Topliss; R J Costello
Journal:  J Med Chem       Date:  1972-10       Impact factor: 7.446

4.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

5.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3.

Authors:  H J Breslin; M J Kukla; D W Ludovici; R Mohrbacher; W Ho; M Miranda; J D Rodgers; T K Hitchens; G Leo; D A Gauthier
Journal:  J Med Chem       Date:  1995-03-03       Impact factor: 7.446

6.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4.

Authors:  W Ho; M J Kukla; H J Breslin; D W Ludovici; P P Grous; C J Diamond; M Miranda; J D Rodgers; C Y Ho; E De Clercq
Journal:  J Med Chem       Date:  1995-03-03       Impact factor: 7.446

7.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.

Authors:  J Ding; K Das; C Tantillo; W Zhang; A D Clark; S Jessen; X Lu; Y Hsiou; A Jacobo-Molina; K Andries
Journal:  Structure       Date:  1995-04-15       Impact factor: 5.006

8.  Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.

Authors:  I W Althaus; J J Chou; A J Gonzales; M R Deibel; K C Chou; F J Kezdy; D L Romero; P A Aristoff; W G Tarpley; F Reusser
Journal:  J Biol Chem       Date:  1993-03-25       Impact factor: 5.157

9.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.

Authors:  M J Kukla; H J Breslin; R Pauwels; C L Fedde; M Miranda; M K Scott; R G Sherrill; A Raeymaekers; J Van Gelder; K Andries
Journal:  J Med Chem       Date:  1991-02       Impact factor: 7.446

Review 10.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

View more
  3 in total

1.  Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.

Authors:  Nitin S Sapre; Swagata Gupta; Nilanjana Pancholi; Neelima Sapre
Journal:  J Comput Aided Mol Des       Date:  2007-12-28       Impact factor: 3.686

2.  Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.

Authors:  Souvik Banerjee; Derek D Norman; Shanshan Deng; Sayo O Fakayode; Sue Chin Lee; Abby L Parrill; Wei Li; Duane D Miller; Gabor J Tigyi
Journal:  Bioorg Chem       Date:  2020-08-26       Impact factor: 5.275

3.  In Silico SAR Studies of HIV-1 Inhibitors.

Authors:  Ismail Hdoufane; Imane Bjij; Mahmoud Soliman; Alia Tadjer; Didier Villemin; Jane Bogdanov; Driss Cherqaoui
Journal:  Pharmaceuticals (Basel)       Date:  2018-07-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.